Cannabis Law Report

DECEMBER 14, 2021

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study. In addition, 66.7%

Clinical Trials 40

Clinical Trials Safety Data Patients 40

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Company plans to initiate Phase II trial with a leading academic institution. These advanced analytics provide a human-centric, data-driven approach to phenotypic discovery for clients.”. Investor Contact: Robert Schatz.

Pharmaceutical 81

Pharmaceutical Data Clinical Trials Research and Development 81

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. Advancements in IP and Drug Development.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

The Cannigma

MARCH 25, 2021

It is also crucial so that the correct data is collected in order to inform further research and clinical trials that are necessary for cannabis medicines to reach the UK National Health Service. The idea behind the MDT series is to place the unfamiliar cannabis medicines into a familiar case discussion format.

Patients 145

Patients Clinical Trials Medicine Events 145

Cannabis Law Report

OCTOBER 28, 2021

Psymposia report… O n Sep 23, 2021, Psymposia staff received an email from the personal email account of Mark Haden — the former Executive Director of psychedelic nonprofit MAPS Canada and current Director of Clinical Trials for Psygen Inc. MAPS Canada’s Data Breach Foreshadows Corporadelic Future.

Data 52

Data Clinical Trials Events Medicine 52

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. These statements relate to future events or future performance. from 2020 to 2030 and generate revenue of $151.7 billion in 2030.

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

AUGUST 17, 2021

Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

JULY 29, 2021

With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com. Forward-looking statements.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A

Clinical Trials 40

Clinical Trials Research and Development Pharmaceutical Events 40

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Guy Goodwin appointed Chief Medical Officer and Danielle Schlosser appointed Senior Vice-President, Clinical Innovation. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

DECEMBER 20, 2021

Data To Support Regulatory Filings in the United States. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Data 40

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. Chief Scientific Officer. MyMD Pharmaceuticals, Inc.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

JULY 9, 2021

Clinical trials involving psychedelic drugs and substances are, however, permitted, provided they comply with both state and federal laws applicable to such trials. While the medical and adult use of certain psychedelic drugs and substances are generally prohibited under U.S.

Data 105

Data Clinical Trials Decriminalization Hemp 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

Veriheal

MAY 3, 2022

The study was conducted by more than 10 researchers, with leads Dr. Jodi Gilman and Dr. Kevin Potter taking responsibility for the integrity and accuracy of the data. Clinical Trial Sample Size. Does the Data Justify the Conclusions? Investigating the Impact of MMJ Cards.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Project CBD

MAY 3, 2023

It’s noteworthy that much of this anecdotal data is supported by findings from preclinical research. Dr. Goldstein: We don’t have clinical trials to say, yes this is definitively beneficial or detrimental for children. But we may be on the cusp of having those trials, which would be very exciting.

Cannabinoids 213

Cannabinoids Sleep Clinical Trials CBD 213

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 105

Treatment Sleep Clinical Trials Data 105

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. Accessed July 25, 2021.

CBD 144

CBD Seed-To-Sale Food Access 144

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. However, in some cases, the risks may outweigh even the proven benefits.

Events 48

Events THC Chronic Pain Sleep 48

CannaMD

MARCH 8, 2020

Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. Screening and testing for use of marijuana are encouraged in clinical settings, especially in the care of young patients presenting with cardiovascular disease. a heart attack).

Patients 104

Patients Marijuana Research and Development Clinical Trials 104

Cannabis Law Report

JULY 28, 2021

The results also provide confidence in the Company’s plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. Previously the Company announced that it had secured FDA Orphan Drug Designation for cepharanthine in the treatment of esophageal cancer. ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JUNE 7, 2021

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. Supera-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. For more information, visit www.mymd.com. 646-536-7331.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. We look forward to providing continuing updates as we advance this drug candidate in the clinic.”.

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

Puff Puff Post

SEPTEMBER 16, 2019

Event details below: Date: Tuesday, September 17th 2019. As a Contract Research Organization specialized in medical cannabis, Santé Cannabis offers consultation, data management and clinical trial services to a diverse range of clients from pharmaceutical, biotech and cannabis industries. Time: 9:00AM to 5:00PM.

Programs 108

Programs Research and Development Education Treatment 108

The Joint Blog

APRIL 21, 2020

This is according to a study published in the Journal of Clinical Medicine Research and epublished by the U.S. For the study researchers with the Nordic Cannabis Research Institute in Denmark reviewed 25 clinical trials assessing the safety and efficacy of CBD in various populations. National Institute of Health.

Clinical Trials 52

Clinical Trials CBD Safety Patients 52

Cannabis Law Report

NOVEMBER 12, 2021

In the event that the Maximum LTV is exceeded, Brown Shipley can make a call on the Guarantors requiring them to place cash with Brown Shipley for the aggregate amount of the excess exposure over the Maximum LTV. OCT is conducting pre-clinical testing and development with pre-clinical trials scheduled for 2022.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

AUGUST 3, 2021

FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration (U.S. For Applied DNA: Investor contact: Sanjay M.

Clinical Trials 81

Clinical Trials Therapy Collective Research and Development 81

Cannabis Law Report

SEPTEMBER 2, 2021

FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration (U.S. For Applied DNA: Investor contact: Sanjay M.

Clinical Trials 76

Clinical Trials Therapy Research and Development Collective 76

Cannabis Law Report

DECEMBER 7, 2021

While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. 1.69, 95% CI [1.20–2.36]) 1), 95%CI [??1.39–(??0.60)])

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

DECEMBER 9, 2021

These describe technology and infrastructure for the collection of precise, multimodal, multivalent data that can be processed via machine learning, artificial intelligence, signal processes, and other statistical methods to yield clinically meaningful output to satisfy the requirements of the IFU.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

NOVEMBER 12, 2021

Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end. Condensed Balance Sheet Data. . . The founding co-chairs are Andrew Monte, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

JANUARY 13, 2020

Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol. Forward-looking statements. 917 280 2424 / 401 500 6570.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Cannabis Law Report

JUNE 7, 2021

1.526 were reduced as expected and consistent with other CDC-reported data on vaccine-induced antibody neutralization against these variants 1. Department of Agriculture (USDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final or conditional approval from the U.S.

Clinical Trials 49

Clinical Trials Research and Development Therapy Supply Chain 49